ROP.SW Roche Holding AG

Healthcare Pharmaceuticals SIX Swiss Exchange
463.81 CHF
Close of Oct 30, 2026
250.53 405.90
Market cap
CHF 320B
P/E
26.2x
P/B
9.72x
ROE
84.1%
Dividend yield
2.62%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ROP.SW undervalued?

Graham number

The Graham number of Roche Holding AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Roche Holding AG fundamental analysis

15 of 22 checks passed

ROE 2/2

High return on equity (84.1%), above 20%.

ROA 1/1

Return on assets (28.0%) is above the industry median (15.1%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (55.4%) is above the 5-year average (-0.6% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (55.4%) is above the industry median (41.6%).

Revenue Growth 0/2

Revenue shrank 2.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (97.3%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 14.7x against interest expense, well covered.

PE vs Market 0/1

PE (26.2x) is above the market median (21.2x).

PE vs Industry 1/1

PE (26.2x) is below the industry median (29.3x).

PBV 0/1

Price to book (9.7x) is above the industry median (8.9x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 254.7, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (2.6%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 65.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Roche Holding AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various dise…

Full company profile